JP2018522888A5 - - Google Patents

Download PDF

Info

Publication number
JP2018522888A5
JP2018522888A5 JP2018501345A JP2018501345A JP2018522888A5 JP 2018522888 A5 JP2018522888 A5 JP 2018522888A5 JP 2018501345 A JP2018501345 A JP 2018501345A JP 2018501345 A JP2018501345 A JP 2018501345A JP 2018522888 A5 JP2018522888 A5 JP 2018522888A5
Authority
JP
Japan
Prior art keywords
isolated polypeptide
seq
nos
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018501345A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018522888A (ja
JP6807606B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/042862 external-priority patent/WO2017011837A2/en
Publication of JP2018522888A publication Critical patent/JP2018522888A/ja
Publication of JP2018522888A5 publication Critical patent/JP2018522888A5/ja
Application granted granted Critical
Publication of JP6807606B2 publication Critical patent/JP6807606B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018501345A 2015-07-16 2016-07-18 多価及び多重特異性ｄｒ５結合融合タンパク質 Active JP6807606B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562193309P 2015-07-16 2015-07-16
US62/193,309 2015-07-16
PCT/US2016/042862 WO2017011837A2 (en) 2015-07-16 2016-07-18 Multivalent and multispecific dr5-binding fusion proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020196358A Division JP7244938B2 (ja) 2015-07-16 2020-11-26 多価及び多重特異性ｄｒ５結合融合タンパク質

Publications (3)

Publication Number Publication Date
JP2018522888A JP2018522888A (ja) 2018-08-16
JP2018522888A5 true JP2018522888A5 (enExample) 2019-07-04
JP6807606B2 JP6807606B2 (ja) 2021-01-06

Family

ID=57757772

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018501345A Active JP6807606B2 (ja) 2015-07-16 2016-07-18 多価及び多重特異性ｄｒ５結合融合タンパク質
JP2020196358A Active JP7244938B2 (ja) 2015-07-16 2020-11-26 多価及び多重特異性ｄｒ５結合融合タンパク質
JP2022191038A Pending JP2023022214A (ja) 2015-07-16 2022-11-30 多価及び多重特異性ｄｒ５結合融合タンパク質
JP2025032594A Pending JP2025084923A (ja) 2015-07-16 2025-03-03 多価及び多重特異性ｄｒ５結合融合タンパク質

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020196358A Active JP7244938B2 (ja) 2015-07-16 2020-11-26 多価及び多重特異性ｄｒ５結合融合タンパク質
JP2022191038A Pending JP2023022214A (ja) 2015-07-16 2022-11-30 多価及び多重特異性ｄｒ５結合融合タンパク質
JP2025032594A Pending JP2025084923A (ja) 2015-07-16 2025-03-03 多価及び多重特異性ｄｒ５結合融合タンパク質

Country Status (25)

Country Link
US (4) US10308720B2 (enExample)
EP (2) EP3322734B1 (enExample)
JP (4) JP6807606B2 (enExample)
KR (2) KR102760380B1 (enExample)
CN (2) CN107922491B (enExample)
AU (3) AU2016291701B2 (enExample)
CA (2) CA3288875A1 (enExample)
CY (1) CY1123615T1 (enExample)
DK (1) DK3322734T3 (enExample)
ES (1) ES2833773T3 (enExample)
HR (1) HRP20201785T1 (enExample)
HU (1) HUE051896T2 (enExample)
IL (4) IL328769A (enExample)
LT (1) LT3322734T (enExample)
MX (2) MX2018000523A (enExample)
NZ (1) NZ777930A (enExample)
PL (1) PL3322734T3 (enExample)
PT (1) PT3322734T (enExample)
RS (1) RS61062B1 (enExample)
RU (2) RU2021111382A (enExample)
SG (1) SG10201912410TA (enExample)
SI (1) SI3322734T1 (enExample)
SM (1) SMT202100066T1 (enExample)
WO (1) WO2017011837A2 (enExample)
ZA (1) ZA201800238B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY200973A (en) 2017-04-11 2024-01-26 Inhibrx Inc Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same
JP2021508478A (ja) * 2017-12-28 2021-03-11 ユリウス・マクシミリアンス−ウニヴェルジテート・ヴュルツブルクＪｕｌｉｕｓ Ｍａｘｉｍｉｌｉａｎｓ−Ｕｎｉｖｅｒｓｉｔａｅｔ Ｗｕｅｒｚｂｕｒｇ ＦｃγＲ非依存性アゴニスト活性がある腫瘍壊死因子（ＴＮＦ）受容体スーパーファミリー（ＴＮＦＲＳＦ）受容体活性化抗体融合タンパク質（ＦｃγＲ非依存性アゴニスト活性があるＴＮＦＲＳＦ受容体活性化抗体融合タンパク質；ＴＲＡＡＦＦＩＡＡ）
CN110305210B (zh) * 2018-03-27 2023-02-28 信达生物制药(苏州)有限公司 新型抗体分子、其制备方法及其用途
TW202010757A (zh) 2018-04-11 2020-03-16 美商英伊布里克斯公司 具有經受限cd3結合的多重特異性多肽構築體以及相關方法及用途
WO2020047705A1 (zh) * 2018-09-03 2020-03-12 安菲尼生命科技有限公司 Dr5单域抗体及其用途
GB201903767D0 (en) * 2019-03-19 2019-05-01 Quadrucept Bio Ltd Multimers, tetramers & octamers
AU2020358898B2 (en) * 2019-10-01 2025-10-16 Epsilogen Ltd Hybrid antibody
WO2022002038A1 (zh) * 2020-06-30 2022-01-06 和铂医药(上海)有限责任公司 免疫细胞衔接器多特异性结合蛋白及其制备和应用
EP4545569A3 (en) * 2020-06-30 2025-10-08 Harbour Biomed (Shanghai) Co., Ltd Binding protein having h2l2 and hcab structures
TWI818276B (zh) * 2020-06-30 2023-10-11 大陸商和鉑醫藥（上海）有限責任公司 Fab-HCAb結構的結合蛋白
CA3208641A1 (en) * 2021-02-19 2022-08-25 Ashraf AMANULLAH Formulations of dr5 binding polypeptides
WO2023196943A1 (en) * 2022-04-08 2023-10-12 Inhibrx, Inc. Dr5 agonist and plk1 inhibitor or cdk inhibitor combination therapy
EP4529455A1 (en) * 2022-05-23 2025-04-02 Inhibrx Biosciences, Inc. Dr5 agonist and iap antagonist combination therapy
CN117285644B (zh) * 2022-06-16 2026-05-15 清华大学 一种相变调节元件及其用途
CN120659804A (zh) 2022-09-28 2025-09-16 维连克治疗有限公司 多价蛋白质及筛选方法
KR20260032566A (ko) * 2023-06-29 2026-03-09 오디세이 테라퓨틱스, 인코포레이티드 항-trailr2 항원-결합 단백질 및 그의 용도

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE914504A1 (en) 1990-12-20 1992-07-01 Ixsys Optimization of binding proteins
US20020147140A1 (en) * 2000-01-31 2002-10-10 Rosen Craig A. Nucleic acids, proteins, and antibodies
KR20070010046A (ko) * 2004-04-06 2007-01-19 제넨테크, 인크. Ｄｒ5 항체 및 그의 용도
BRPI0518994A2 (pt) 2004-12-31 2008-12-02 Biogen Idec Inc anticorpos ou polipeptÍdeos que se ligam a br3, seus usos e formulaÇÕes lÍquidas
CA2598889A1 (en) 2005-02-24 2006-08-31 Cemines, Inc. Compositions and methods for classifying biological samples
CA2619725C (en) 2005-08-18 2016-06-07 Ramot At Tel Aviv University Ltd. Single chain antibodies against beta-amyloid peptide
EP1966242A1 (en) 2005-12-06 2008-09-10 Domantis Limited Ligands that have binding specificity for egfr and/or vegf and methods of use therefor
DK1987178T3 (en) 2006-02-20 2015-04-20 Phylogica Ltd Process for the construction and screening of peptide structure libraries
JP2008133206A (ja) 2006-11-28 2008-06-12 Yokohama City Univ 緑膿菌に対して感染防御能を誘導できる医薬組成物
SG186017A1 (en) 2007-11-30 2012-12-28 Kalobios Pharmaceuticals Inc Antibodies to the pcrv antigen of pseudomonas aeruginosa
LT2285408T (lt) * 2008-06-05 2019-01-25 Ablynx N.V. Aminorūgščių sekos, nukreiptos prieš viruso apvalkalo baltymus, ir tokias sekas turintys polipeptidai, skirti virusinių ligų gydymui
US20110166076A1 (en) * 2008-09-10 2011-07-07 Bac Ip B.V. Antigen-binding proteins that inhibit superantigens for the treatment of skin diseases
EP2408475B1 (en) 2009-03-18 2017-11-15 Wake Forest University Health Sciences Flagellin fusion proteins and use thereof to induce immune responses against pseudomonas aeruginosa
US20100281003A1 (en) 2009-04-02 2010-11-04 New York University System and uses for generating databases of protein secondary structures involved in inter-chain protein interactions
CN101717775B (zh) * 2009-11-13 2012-01-04 厦门大学 抗人死亡受体5的单链抗体基因
HRP20251657T1 (hr) 2009-12-14 2026-02-13 Ablynx N.V. Imunoglobulinska protutijela s jednostrukom varijabilnom domenom protiv ox40l, konstrukti i njihova terapijska upotreba
US9120855B2 (en) * 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
US8623369B2 (en) 2010-04-27 2014-01-07 National Research Council Of Canada Anti-ICAM-1 single domain antibody and uses thereof
US8877899B2 (en) 2010-09-27 2014-11-04 Morphosys Ag Anti-CD38 antibody and lenalidomide or bortezomib for the treatment of multipe myeloma and NHL
CA2815888C (en) 2010-10-25 2020-06-30 National Research Council Of Canada Clostridium difficile-specific antibodies and uses thereof
CA2822684A1 (en) 2010-12-23 2012-06-28 Intercell Austria Ag Oprf/i agents and their use in hospitalized and other patients
MY167125A (en) 2011-08-17 2018-08-13 Glaxo Group Ltd Modified proteins and peptides
SMT202000091T1 (it) 2011-10-13 2020-05-08 Bristol Myers Squibb Co Polipeptidi anticorpali che antagonizzano cd40l
CN103906533A (zh) 2011-11-07 2014-07-02 米迪缪尼有限公司 多特异性和多价结合蛋白及其用途
CN104169304A (zh) 2011-12-20 2014-11-26 阿达拉塔合伙有限公司 作为pcsk9抑制剂的单域抗体
JP6415987B2 (ja) 2012-03-02 2018-10-31 アブリンクス エン．ヴェー． シュードモナス・エルギノーサのＰｃｒＶに結合する単一可変ドメイン抗体
WO2013167883A1 (en) 2012-05-07 2013-11-14 The University Court Of The University Of Aberdeen Single domain binding molecule
EP2684896A1 (en) * 2012-07-09 2014-01-15 International-Drug-Development-Biotech Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof
WO2014043509A2 (en) 2012-09-13 2014-03-20 Novartis Ag Antigen binding molecule with terminal modifications
US20150284450A1 (en) 2012-11-06 2015-10-08 Medimmune, Llc Combination therapies using anti-pseudomonas psl and pcrv binding molecules
CN102924600B (zh) * 2012-11-14 2013-10-30 河南大学 死亡受体5激动性多价抗体及其在制备抗肿瘤药物中的应用
WO2014111550A1 (en) 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Modified anti-serum albumin binding proteins
US9862777B2 (en) 2013-05-28 2018-01-09 Vib Vzw Single domain antibodies against SOD1 and their use in medicine
KR20160103007A (ko) * 2014-01-10 2016-08-31 각코호진 데이쿄 헤이세이 다이가쿠 재조합 편성 혐기성 그램 양성균

Similar Documents

Publication Publication Date Title
RU2021111382A (ru) Мультивалентные и мультиспецифические гибридные белки, связывающиеся с dr5
JP2020508655A5 (enExample)
JP2022512684A5 (enExample)
JP2021503455A5 (enExample)
JP2019116474A5 (enExample)
JP2020525032A5 (enExample)
JP2022512132A5 (enExample)
JP2021508469A5 (enExample)
JP2023551027A5 (enExample)
JP2019527553A5 (enExample)
JP2017504578A5 (enExample)
JP2018523493A5 (enExample)
JP2019532619A5 (enExample)
JP2010502183A5 (enExample)
JP2018520993A5 (enExample)
EP3625249A1 (en) Method of preparing ph-dependent antibodies
RU2019121086A (ru) Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1)
JP2021520832A5 (enExample)
JP2009225799A5 (enExample)
RU2018106452A (ru) Поливалетные и полиспецифичные gitr-связывающие слитые белки
JP2018526981A5 (enExample)
JP2012501670A5 (enExample)
JP2013506428A5 (enExample)
JP2012525829A5 (enExample)
JP2022545647A5 (enExample)